Everything below concerns albumin binding. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-03-22. Where a claim depends on a specific study, the study is described rather than over-claimed.
GLP-1 receptors are expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises cyclic AMP, enhances glucose-dependent insulin secretion, and suppresses glucagon release when blood glucose is high. Effects on gastric emptying and on hypothalamic appetite circuits reduce energy intake. Because insulin release remains glucose-dependent, the risk of hypoglycemia is low when the drug is used alone. The precise contribution of each pathway to body weight change in humans remains an area of active investigation.
Clinical studies of semaglutide generally measure glycated hemoglobin, fasting plasma glucose, body weight, and composite cardiovascular endpoints. The SUSTAIN program enrolled adults with type 2 diabetes, while the STEP program focused on obesity without diabetes. Administration follows a stepwise escalation schedule designed to limit gastrointestinal effects during the first weeks. Reported outcomes include mean percentage weight change, the proportion of participants reaching defined weight-loss thresholds, and rates of nausea, vomiting, and diarrhea. Long-term data on durability after treatment stops are still limited and remain a topic of ongoing research.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | Peptide backbone with a C18 fatty diacid side chain |
| Molecular weight | Approximately 4113 Da | Consistent with a 31-residue peptide plus linker |
| Appearance | White to off-white powder | Lyophilized solid; hygroscopic if left open |
| Solubility class | Sparingly soluble to soluble in water | Varies with pH and ionic strength |
| Typical analytical method | Reversed-phase HPLC with UV detection | Often paired with mass spectrometry for identity |
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.
Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class, a group of synthetic peptides that imitate an incretin hormone released by intestinal L cells after food intake. Native GLP-1 circulates for only a few minutes because dipeptidyl peptidase-4 cleaves it rapidly. The hormone acts on pancreatic islets, the gastrointestinal tract, and several brain regions. Because the natural peptide is short-lived, development work concentrated on analogues that keep receptor activity while resisting enzymatic breakdown and renal clearance.
On inhalation and exhalation air moves through the airways in the same direction, thus creating a unidirectional airflow through the lungs. A similar system is found in birds, monitor lizards and iguanas. Most reptiles lack a secondary palate, meaning that they must hold their breath while swallowing. Crocodilians have evolved a bony secondary palate that allows them to continue breathing while remaining submerged (and protect their brains against damage by struggling prey). Skinks (family Scincidae) also have evolved a bony secondary palate, to varying degrees. Snakes took a different approach and extended their trachea instead. Their tracheal extension sticks out like a fleshy straw, and allows these animals to swallow large prey without suffering from asphyxiation.
Beverly Gail Allitt (born 4 October 1968) is an English serial killer who was convicted of murdering three infants and an 11-year-old boy, attempting to murder three others, and causing grievous bodily harm to six more at Grantham and Kesteven Hospital, Lincolnshire, between February and April 1991. She committed the murders as a state enrolled nurse on the hospital's children's ward. Allitt administered large doses of insulin to at least two of her victims and a large air bubble was found in the body of another, but police were initially unable to establish how all of the attacks were carried out. In May 1993, Allitt received 13 life sentences at Nottingham Crown Court. The sentencing judge, Mr Justice David Latham, told Allitt that she was "a serious danger" to others and was unlikely ever to be considered safe enough to be released. Allitt is currently detained at Rampton Secure Hospital in Nottinghamshire. She became eligible for release on parole after her minimum tariff of 30 years' imprisonment expired in November 2021.
Listeria monocytogenes, some species of Rickettsia, Shigella flexneri and other intracellular germs escape from phagocytic vacuoles by coating themselves with a capsule of actin filaments. L. monocytogenes and S. flexneri both generate a tail in the form of a "comet tail" that gives them mobility. Each species exhibits small differences in the molecular polymerization mechanism of their "comet tails". Different displacement velocities have been observed, for example, with Listeria and Shigella found to be the fastest. Many experiments have demonstrated this mechanism in vitro. This indicates that the bacteria are not using a myosin-like protein motor, and it appears that their propulsion is acquired from the pressure exerted by the polymerization that takes place near to the microorganism's cell wall. The bacteria have previously been surrounded by ABPs from the host, and as a minimum the covering contains Arp2/3 complex, Ena/VASP proteins, cofilin, a buffering protein and nucleation promoters, such as vinculin complex. Through these movements they form protrusions that reach the neighbouring cells, infecting them as well so that the immune system can only fight the infection through cell immunity. The movement could be caused by the modification of the curve and debranching of the filaments. Other species, such as Mycobacterium marinum and Burkholderia pseudomallei, are also capable of localized polymerization of cellular actin to aid their movement through a mechanism that is centered on the Arp2/3 complex.
=== Skin depigmentation === Hydroquinone is used topically for skin whitening, either alone or in combination with other topical agents. It is the most effective treatment for hyperpigmentation. It does not have the same predisposition to cause dermatitis as metol does. This is a prescription-only ingredient in some countries, including the member states of the European Union under Directives 76/768/EEC:1976. Its skin-lightening effect was first reported in 1936. In the 1950s, it was available as part of a sunscreen formulation in southern regions of the USA. Its skin-lightening effect was observed as a fortuitous side-effect. In 1961, it was trialed for hyperpigmentation. In 1975, a topical combination of hydroquinone 5%, tretinoin 0.1% and dexamethasone 0.1% was trialed for melasma, ephelides and postinflammatory hyperpigmentation. In 2006, United States Food and Drug Administration (FDA) revoked its previous approval of hydroquinone and proposed a ban on all over-the-counter preparations. The FDA officially banned hydroquinone in 2020 as part of a larger reform of the over-the-counter drug review process. The FDA stated that hydroquinone cannot be ruled out as a potential carcinogen. This conclusion was reached based on the extent of absorption in humans and the incidence of neoplasms in rats in several studies where adult rats were found to have increased rates of tumours, including thyroid follicular cell hyperplasias, anisokaryosis (variation in nuclei sizes), mononuclear cell leukemia, hepatocellular adenomas and renal tubule cell adenomas.
The two substrates of this enzyme are allyl alcohol and oxidsed nicotinamide adenine dinucleotide phosphate (NADP+). Its products are acrolein, reduced NADPH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is allyl-alcohol:NADP+ oxidoreductase.
Sources: en.wikipedia.org
2 NaNH2 + N2O → NaN3 + NaOH + NH3 These reactions are the basis of the industrial route, which produces about 250 tons per year in 2004, with production increasing due to the increased use of airbags.
To overcome the limit, a small part of the system is treated quantum-mechanically (typically active-site of an enzyme) and the remaining system is treated classically. In more sophisticated implementations, QM/MM methods exist to treat both light nuclei susceptible to quantum effects (such as hydrogens) and electronic states. This allows generating hydrogen wave-functions (similar to electronic wave-functions). This methodology has been useful in investigating phenomena such as hydrogen tunneling. One example where QM/MM methods have provided new discoveries is the calculation of hydride transfer in the enzyme liver alcohol dehydrogenase. In this case, quantum tunneling is important for the hydrogen, as it determines the reaction rate.
=== Li–Lu === Andreas Libavius (1555–1616), German doctor and alchemist who discovered how prepare hydrochloric acid, ammonium sulfate, etc. Carl Theodore Liebermann (1842–1914), German chemist, known for synthesis of alizarin Willard Libby (1908–1980), American chemist known for development of radiocarbon dating, 1960 Nobel Prize in Chemistry Justus von Liebig (1803–1873), German inventor and pioneer in agricultural and biological chemistry Karl Paul Link (1901–1978), American biochemist, discovered the anticoagulant warfarin John Wilfrid Linnett (1913–1975), British chemist at the Universities of Oxford and Cambridge, known for contributions to theoretical chemistry William Lipscomb (1919–2011), American chemist known for work in nuclear magnetic resonance, theoretical chemistry, boron chemistry, and biochemistry; 1976 Nobel Prize in Chemistry Joseph Lister, 1st Baron Lister (1827–1912), English surgeon known for recognising that putrefaction in wounds is caused by germs Arthur H. Livermore (1915–2009), American science educator and chemist who contributed to the synthesis of penicillin Mikhail Lomonosov (1711–1765), Russian scientist, anticipated the kinetic-molecular theory by 100 years H.
== Epidemiology == Globally, the prevalence and incidence of pulmonary fibrosis has been studied in the United States, Norway, Czech Republic, Greece, United Kingdom, Finland, and Turkey, with only two studies in Japan and Taiwan. But most of these studies were of people already diagnosed with pulmonary fibrosis, which lowers the diagnosis sensitivity, so that the prevalence and incidence has ranged from 0.7 per 100,000 in Taiwan to 63.0 per 100,000 in the U.S., and the published incidence has ranged from 0.6 per 100,000 person years to 17.4 per 100,000 person years. The mean age of all pulmonary fibrosis patients is between 65 and 70 years, making age a criterion of its own. Aging respiratory systems are much more vulnerable to fibrosis and stem cell depletion.
Sources: en.wikipedia.org
== Structure == Although no crystallographic x-ray diffraction analyses have been published that depict the entire structure of ADAM10, one domain has been studied using this technique. The disintegrin and cysteine-rich domain (shown to the right) plays an essential role in regulation of protease activity in vivo. Recent experimental evidence suggests that this region, which is distinct from the active site, may be responsible for substrate specificity of the enzyme. It is proposed that this domain binds to particular regions of the enzyme's substrate, allowing peptide bond hydrolysis to occur in well defined locations on certain substrate proteins. The proposed active site of ADAM10 has been identified by sequence analysis, and is identical to enzymes in the Snake Venom metalloprotein domain family. The consensus sequence for catalytically active ADAM proteins is HEXGHNLGXXHD. Structural analysis of ADAM17, which has the same active site sequence as ADAM10, suggests that the three histidines in this sequence bind a Zn2+ atom, and that the glutamate is the catalytic residue.
== Biosynthesis == In the morphine biosynthetic pathway, salutaridinol is derived in three steps from (R)-reticuline. First, (R)-reticuline undergoes an oxidation at each of its phenol rings mediated by the cytochrome P-450-dependent monooxygenase salutaridine synthase. These phenol group oxidations yield a diradical species that undergoes ortho coupling to the phenol group of the tetrahydroisoquinoline and para coupling to the benzyl group to create the salutaridinol precursor salutaridine. A stereospecific reduction of the salutaridine carbonyl group by salutaridine: NADPH 7-oxidoreductase then generates salutaridinol.
== Side effects == Seltorexant is reported to be safe and well-tolerated. Side effects of seltorexant observed in clinical trials so far have included somnolence, fatigue, dizziness, headache, abdominal discomfort, and nightmares.
Over the next three years, 1st SFG (A) members built an significant record in the Philippines training six light infantry battalions, three light reaction companies from the Armed Forces of the Philippines (AFP), treating over 31,000 Filipinos in MEDCAP events, helping to professionalize the AFP, and providing operations and intelligence fusion teams to actively assist the AFP in targeting militant cells. Throughout 2003–2004, the 1st SFG (A) deployed numerous personnel in support of Operation Iraqi Freedom and Operation Enduring Freedom in Iraq and Afghanistan respectively. By November 2004 the unit deployed an entire battalion to Afghanistan as part of the Combined Joint Special Operations Task Force- Afghanistan (CJSOTF-A). Today, 1st SFG (A) supported the global war on terrorism with operations in the Philippines, Iraq and Afghanistan as well as maintaining US security relationships with partner nations throughout the Pacific until 2021.
Hackenberger's research at the Leibniz Research Institute focuses on chemical strategies to functionalize proteins and antibodies using highly selective chemical reactions to generate protein-based therapeutics against cancer, Alzheimer's and viral infections. A particular focus of Hackenberger's research group is the engineering of new reactions for the modification and cellular delivery of proteins and antibodies to advance their use in biological and pharmacological research.
Sources: en.wikipedia.org
It is given either as a once-weekly subcutaneous injection or as an oral tablet taken once daily. The two forms use different absorption strategies, so they are not interchangeable on a milligram-for-milligram basis.
Structural modifications, including a fatty acid side chain and non-natural amino acid substitutions, slow enzymatic breakdown and promote albumin binding. These changes support once-weekly dosing rather than twice-daily administration.
The pathways involving insulin, glucagon, gastric emptying, and appetite signaling are well described. How much each pathway contributes to weight reduction in a given person is not fully established.
Native GLP-1 is a short-lived peptide cleared within one to two minutes by dipeptidyl peptidase-4 and related enzymes. Semaglutide keeps the receptor-binding backbone but adds substitutions and a lipid chain. These changes block the main cleavage site and allow reversible albumin binding, extending the half-life to roughly 165 hours.